ClinicalTrials.gov record
Recruiting Phase 2 Interventional

A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

ClinicalTrials.gov ID: NCT04683679

Public ClinicalTrials.gov record NCT04683679. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 7:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase II Study of Pembrolizumab and Ablative Radiotherapy With or Without Olaparib in Metastatic Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancers : Initial Test Cohorts of a Platform Trial to Sequentially Investigate Immunotherapy Combinations for the Augmentation of Immune Responses

Study identification

NCT ID
NCT04683679
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Enrollment
34 participants

Conditions and interventions

Interventions

  • Olaparib Drug
  • Pembrolizumab Drug
  • Radiation Radiation

Drug · Radiation

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 20, 2021
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026
Last update posted
Feb 16, 2026

2021 – 2027

United States locations

U.S. sites
7
U.S. states
2
U.S. cities
7
Facility City State ZIP Site status
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) Basking Ridge New Jersey 07920 Recruiting
Memorial Sloan Kettering Monmouth (Limited Protocol Activities) Middletown New Jersey 07748 Recruiting
Memorial Sloan Kettering Bergen (Limited Protocol Activities) Montvale New Jersey 07645 Recruiting
Memorial Sloan Kettering Commack (Limited Protocol Activities) Commack New York 11725 Recruiting
Memorial Sloan Kettering Westchester (Limited Protocol Activities) Harrison New York 10604 Recruiting
Memorial Sloan Kettering Cancer Center (All Protocol Activities) New York New York 10065 Recruiting
Memorial Sloan Kettering Nassau (All Protocol Activities) Uniondale New York 11553 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04683679, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 16, 2026 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04683679 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →